One of them is Director of Regulatory Affairs...
The primary responsibility of this position will be oversight of all regulatory affairs activities pertaining to the underlying strategy and conduct of Phase I-III clinical trials in a biopharmaceutical company. Significant leadership skills will be required to oversee group activities to develop and execute the regulatory strategy for Phase I-III clinical development. The leader will assess the regulatory strategy for potential drug / biological development candidates, manage all IND submissions and meetings, manage regulatory agency communication and negotiation, and ensure compliance with all international regulatory requirements.
P3 VGX-3100 is about to start, by early q3 is my best guess.
INO will sure get the funding. It's about the matter of when and how much.
Anyone care to disagree?
When someone agreed to invest $10M into ONCS at $1.82 per share, he would expect the sp will be double or more in less than 12 months...Buy and Hold for max profit
INO stock price hits $20 by EOY 16 is no surprise to me. Just a matter of time
It's not a surprised if we hear about INO-5150 Prostate cancer P1 interim data or INO-1400 hTERT P1 interim data or FDA approval to proceed VGX-3100 to P3 study or Zika funding from US Govt, or...
Looks like people are buying now. Lot of good news are due in few weeks.
Man, that is bad news...The world needs vaccine to treat and prevent Zika virus...Olympics in Brazil is in August. time is near.
INO's vaccine to the rescue.
From medical express,
Using gene editing technology, researchers at the Lewis Katz School of Medicine at Temple University have, for the first time, successfully excised a segment of HIV-1 DNA - the virus responsible for AIDS - from the genomes of living animals. The breakthrough, described online this month in the journal Gene Therapy, is a critical step in the development of a potentially curative strategy for HIV infection.
"In a proof-of-concept study, we show that our gene editing technology can be effectively delivered to many organs of two small animal models and excise large fragments of viral DNA from the host cell genome," explained lead investigator on the study, Kamel Khalili, PhD, Laura H. Carnell Professor and Chair of the Department of Neuroscience, Director of the Center for Neurovirology, and Director of the Comprehensive NeuroAIDS Center at the Lewis Katz School of Medicine at Temple University (LKSOM).
Sounds like INO..
Good, waiting patiently to buy back ~ 1.30 level...Merck's Keytruda success may benefit this little ONCS..
CHICAGO (AP) — A new kind of drug for the deadliest form of skin cancer helped some patients survive for at least three years, a study shows. It's a remarkable advance for patients who until recently faced dismal chances of living for more than a few months.
About 40 percent of melanoma patients in the study were still alive three years later. The drug, which targets the immune system, was used to treat former President Jimmy Carter, who was diagnosed with melanoma that had spread to his brain.
"This is incredible," Dr. Caroline Robert, the study's lead author, said of the results released Wednesday. "I spend my time telling my residents that these patients would be dead if it was five years ago."
The drug, Keytruda, is among a new class of genetically engineered antibody-based medicines. They block proteins that prevent the body's disease-fighting immune system from attacking cancer cells. This immunotherapy approach is transforming treatment for several kinds of cancer with drugs that are often less toxic than chemotherapy.
The latest findings for Merck's Keytruda (kee-TROO'-duh) are among the best long-term data ever for treating melanoma that has spread to other organs, Robert and other cancer experts said.
The U.S. House of Representatives passed a Republican-backed bill Wednesday night to combat the Zika virus that the White House has already threatened to veto as inadequate.
The bill, sponsored by Rep. Hal Rogers, R-Kentucky, chairman of the Appropriations Committee, would provide $622 million to fight the virus — less than a third of what President Barack Obama asked for three months ago.
The measure next must be reconciled with a compromise Zika bill the Senate passed Tuesday, which would provide about $1.1 billion, or roughly two-thirds of what the White House wants.
It's too early to even talk about it...but it's also possible. If P1 gets start in early June and INO has enough data to convince WHO that the vaccine is safe and could be used for prevention, then the possibility is high
Also the timing to release Large animal study was perfect to me...who else have the furthest Zika testing than INO? We are all expecting the zika funding to INO but not sure how much
The Senate approved $1.1B funding for Zika yesterday. The House proposed $620M and schedule to vote today. Then the bills would be sent to President to sign, then it might take weeks to allocate the funding...The agencies probably have the list of promising company that can develop and manufactory the Vaccine to treat and prevent Zika..We could hear about Zika funding by early June, imo